EGTX Share Price Performance
SEK 0
-3.67 (-100.00%)
Price SEK 0
Fair ValueSEK 1.60
Share Pricen/a
Egetis Therapeutics AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
EGTX Community Narratives
AN
Fair Value SEK 1.6 260.6% overvalued intrinsic discount
Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 9.78 41.0% undervalued intrinsic discount
Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value SEK 14.5 60.2% undervalued intrinsic discount
Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside
Catalysts About Egetis Therapeutics Egetis Therapeutics is a specialty pharmaceutical company focused on developing and commercializing Emcitate, tiratricol, for patients with MCT8 deficiency. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 14.5
60.2% undervalued intrinsic discount
Fair Value
Profit Margin
40.94%
Future PE
7.93x
Price in 2029
SEK 16.9
Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects
Catalysts About Egetis Therapeutics Egetis Therapeutics develops and commercializes treatments for rare endocrine and genetic disorders, with a focus on MCT8 deficiency. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 1.6
260.6% overvalued intrinsic discount
Fair Value
Profit Margin
17.97%
Future PE
12.85x
Price in 2029
SEK 1.86
Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook
Catalysts About Egetis Therapeutics Egetis Therapeutics is a specialty biopharmaceutical company focused on developing and commercializing innovative treatments for patients with rare endocrine and metabolic disorders. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 9.78
41.0% undervalued intrinsic discount
Fair Value
Profit Margin
19.7%
Future PE
19.92x
Price in 2028
SEK 11.39
Trending Discussion
Recently Updated Narratives
AN
Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside
Fair Value: SEK 14.5 60.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects
Fair Value: SEK 1.6 260.6% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook
Fair Value: SEK 9.78 41.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Egetis Therapeutics AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 29, 2026
- -0.87
- 19.87%
- -548.88%
- 22.6%
About EGTX
- Founded
- 2006
- Employees
- 42
- CEO
- WebsiteView website
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
